Medical Technology Innovation Forum to focus on personalized health care, medicine

Bill Carpou

OCTANe’s 14th annual Medical Technology Innovation Forum, a meeting centered on bringing together investors, executives and entrepreneurs in the medical technology industry, will focus on personalized health care and medicine this year.

The forum will be held at the Newport Beach Marriott Hotel and Spa in Newport Beach from Oct. 28 to Oct. 29. This year’s meeting is slated to host more than 700 attendees — a notable increase from the 150 who attended the first meeting in 2005, according to Bill Carpou, CEO of OCTANe.

“We're now getting more of a broader domestic and even an international crowd,” Carpou told Healio. “It's an opportunity to convene the ecosystem.”

The forum is slated to host approximately 75 speakers and panelists, 150 investors and entrepreneurs as well as 250 CEOs and senior management from various companies and institutions.

Keeping in line with the theme of personalized care, the first day of the forum will feature presentations on the future of health care and role of personalized medicine, as well as updates in clinical trials and European Union regulations related to Brexit.

Day two of the meeting will feature a “Breakfast with Experts” event that encourages attendees to network with industry experts as well as alumni from OCTANe’s LaunchPad, a business accelerator for up-and-coming entrepreneurs in medical technology.

“We really try to reach out to a broader base of potential interested parties that can participate in something like this,” Carpou said in an interview. “What we wanted to do was bring something out that was health care-oriented, but you didn't really have to be in the health care industry. We're saying, ‘Hey, if you're a consumer and you want to come find out about certain things in personalized medicine, that's inside of this platform.”

Panelists and speakers will include Mike Mussallem, chairman and CEO of Edwards Lifesciences; Jim Fallon, PhD, M.S., professor emeritus of anatomy and neurobiology and professor of psychiatry and human behavior at the University of California, Irvine; Marina Bejanian, PhD, executive director of clinical development at Allergan, and others. OCTANe’s overarching goal with both the forum and Launchpad is high-paying job creation, according to Carpou, with a target of 55,000 new jobs by 2030.

“We focus on the practical application of the technologies that we're working with,” Carpou said. “They'll be clinical applications, but a lot of that applies to: ‘How do you use this in your business? How do you grow your business? If you're a physician, how can you scale and grow your business?”

Pre-registration is available via OCTANe’s website. General admission is $799, $849 for admission and an annual membership, $3,000 for a company package which includes five admission passes and $549 for members and sponsors. by Eamon Dreisbach

Disclosures: Carpou is the CEO of OCTANe. Healio’s Ocular Surgery News is the official media sponsor for the Medical Technology Innovation Forum.

Bill Carpou

OCTANe’s 14th annual Medical Technology Innovation Forum, a meeting centered on bringing together investors, executives and entrepreneurs in the medical technology industry, will focus on personalized health care and medicine this year.

The forum will be held at the Newport Beach Marriott Hotel and Spa in Newport Beach from Oct. 28 to Oct. 29. This year’s meeting is slated to host more than 700 attendees — a notable increase from the 150 who attended the first meeting in 2005, according to Bill Carpou, CEO of OCTANe.

“We're now getting more of a broader domestic and even an international crowd,” Carpou told Healio. “It's an opportunity to convene the ecosystem.”

The forum is slated to host approximately 75 speakers and panelists, 150 investors and entrepreneurs as well as 250 CEOs and senior management from various companies and institutions.

Keeping in line with the theme of personalized care, the first day of the forum will feature presentations on the future of health care and role of personalized medicine, as well as updates in clinical trials and European Union regulations related to Brexit.

Day two of the meeting will feature a “Breakfast with Experts” event that encourages attendees to network with industry experts as well as alumni from OCTANe’s LaunchPad, a business accelerator for up-and-coming entrepreneurs in medical technology.

“We really try to reach out to a broader base of potential interested parties that can participate in something like this,” Carpou said in an interview. “What we wanted to do was bring something out that was health care-oriented, but you didn't really have to be in the health care industry. We're saying, ‘Hey, if you're a consumer and you want to come find out about certain things in personalized medicine, that's inside of this platform.”

Panelists and speakers will include Mike Mussallem, chairman and CEO of Edwards Lifesciences; Jim Fallon, PhD, M.S., professor emeritus of anatomy and neurobiology and professor of psychiatry and human behavior at the University of California, Irvine; Marina Bejanian, PhD, executive director of clinical development at Allergan, and others. OCTANe’s overarching goal with both the forum and Launchpad is high-paying job creation, according to Carpou, with a target of 55,000 new jobs by 2030.

“We focus on the practical application of the technologies that we're working with,” Carpou said. “They'll be clinical applications, but a lot of that applies to: ‘How do you use this in your business? How do you grow your business? If you're a physician, how can you scale and grow your business?”

Pre-registration is available via OCTANe’s website. General admission is $799, $849 for admission and an annual membership, $3,000 for a company package which includes five admission passes and $549 for members and sponsors. by Eamon Dreisbach

Disclosures: Carpou is the CEO of OCTANe. Healio’s Ocular Surgery News is the official media sponsor for the Medical Technology Innovation Forum.